|
Living Medical Textbook From Projects In Knowledge |
|
| Chapter 1 Chemotherapy in Recurrent or Metastatic Cervical Cancer Last Reviewed: August 23, 2010 |
||
| Chapter 2 Current Management of Endometrial Cancer Last Reviewed: August 23, 2010 |
||
| Chapter 3 Frontline Management of Ovarian Cancer Last Reviewed: August 23, 2010 |
||
| Chapter 4 Recurrent Ovarian Cancer: State of the State Last Reviewed: August 23, 2010 |
||
| Chapter 5 Early Breast Cancer—Tumor Genetic Profiling in The 21st Century Last Reviewed: August 23, 2010 |
||
| Chapter 6 Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer Last Reviewed: August 23, 2010 |
||
|
|
||||||||||
| Chapter 1 – Chemotherapy in Recurrent or Metastatic Cervical Cancer | ||||||||||
|
||||||||||
|
Activity Goal The goal of this CME activity is to examine current and emerging strategies for treating and managing patients with breast, ovarian, cervical and endometrial cancers. |
||||||||||
|
Target Audience This CME activity is designed for medical oncology clinicians, gynecologists, primary care physicians and other clinicians who interact with and/or treat women with breast, ovarian, uterine/endometrial, and cervical cancers. |
||||||||||
Learning Objectives
|
||||||||||
| top |
||||||||||
|
CME Information: Physicians
Statement of Accreditation Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. top |
||||||||||
|
Disclosure Information The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR). Bradley J. Monk, MD, FACOG, FACS, has received grant/research support from GlaxoSmithKline; and in on the speakers bureau of GlaxoSmithKline, Merck & Co, Inc, and QIAGEN, NV. Off-Label Drug Disclosure: Single-agent cisplatin, single-agent topotecan, gemcitabine, paclitaxel, vinorelbine, docetaxel, bevacizumab are not approved by the FDA for the treatment of cervical cancer. Nancy J. Nordenson, MT (ASCP), MFA (medical writer), has disclosed no significant relationships. Peer Reviewer has disclosed no significant relationships. Projects In Knowledge’s staff members have no significant relationships to disclose. top |
||||||||||
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||
|
||||||||||
|
|
|
|
|
These independent CME activities are supported by educational grants from
Bristol-Myers Squibb Genentech Inc. Novartis Pharmaceutical Corporation OrthoBiotech Inc. Pfizer Inc.. |
|
|
Release Date: October 3, 2008. Termination Date: September 15, 2010. |
|
Estimated time for completion of this activity: 2.0 hours |
|
CME Instructions To obtain CME credit for this activity:
There is no fee for this activity. |
|
